Clinical trials: Ticagrelor
ST-elevation Myocardial Infarction
Evaluation of Myocardial Reperfusion After Primary PCI in Patients With High Platelet Reactivity Treated by Cangrelor or Not
This study aims to evaluate the impact on myocardial reperfusion and residual thrombotic burden of adding Cangrelor -a potent and immediate P2Y12 inhibitor- to ticagrelor in primary PCI patients with high on ticagrelor platelet…
- Trial name
- ERMIT (NCT04927949)
- Testing
- cangrelor perfusion during PCI, standard PCI
- Where
- France
- Volunteers
- 128 people
- Sponsor
- University Hospital, Caen
Dyspnea
Trial of Caffeine to Alleviate Dyspnea Related to Ticagrelor
Ticagrelor treatment is associated with increased rates of dyspnea, where previous studies have implied a possible role of adenosine.
- Trial name
- TROCADERO (NCT02311088)
- Testing
- Caffeine
- Where
- 9 sites in Sweden
- Volunteers
- 26 people
- Sponsor
- Uppsala University
Coronary Artery Disease
STEEL Percutaneous Coronary Intervention
The principal hypothesis of this study is that two different maintenance regimens of ticagrelor are safe, tolerable and associated with significant inhibition of erythrocyte adenosine reuptake compared to clopidogrel in patients…
- Trial name
- STEEL-PCI (NCT02327624)
- Testing
- Clopidogrel, Ticagrelor 60, Ticagrelor 90
- Where
- United Kingdom
- Volunteers
- 180 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Pneumonia, Community Acquired Pneumonia
Targeting Platelet-Leukocyte Aggregates in Pneumonia With Ticagrelor
The hypothesis to be tested is that ticagrelor (Brilinta™) will reduce platelet activation and markers of inflammation in patients with pneumonia.
- Conditions
- Pneumonia, Community Acquired Pneumonia, Hospital Acquired Pneumonia, Acute Lung Injury
- Trial name
- XANTHIPPE (NCT01883869)
- Testing
- ticagrelor
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Kentucky
Stroke, Transient Ischemic Attack
Clopidogrel With Aspirin in High-risk Patients With Acute Non-disabling Cerebrovascular Events II
The primary objective of this trial is to assess the effects of ticagrelor plus aspirin versus clopidogrel plus aspirin on reducing the 3-month risk of any stroke (both ischemic and hemorrhagic, primary outcome) when initiated…
- Trial name
- CHANCE-2 (NCT04078737)
- Testing
- Ticagrelor and Aspirin, Clopidogrel and Aspirin
- Where
- 214 sites in China
- Volunteers
- 6,412 people
- Sponsor
- Beijing Tiantan Hospital
Gout, Coronary Artery Disease
Uric Acid Study in Healthy Male Volunteers
This study is being conducted to examine the effect of AZD6140 on the levels of certain chemicals in subjects' blood and urine.
- Trial name
- NCT00738842
- Testing
- AZD6140
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca